Key facts
- This page summarizes John Johnson's Form 4 filing for Applied Therapeutics, Inc. (APLT).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 20 Dec 2024, 20:30.
John Johnson - 19 Dec 2024 Form 4 Insider Report for Applied Therapeutics, Inc. (APLT)
- Reporting relationship
- Executive Chairman, Director
- Issuer ticker
- APLT
- Reported as of
- 19 Dec 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Dec 2024, 20:30:54 UTC
- Prior SEC filing
- 04 Sep 2024
- Next SEC filing
- 27 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Leslie D. Funtleyder, as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
John Johnson filed Form 4 for Applied Therapeutics, Inc. (APLT) on 20 Dec 2024.
Change
- Previous filing in this sequence was filed on 04 Sep 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +500,000
- Change %
- Price
- $0.000000
- Shares after
- 500,000
- Date
- 19 Dec 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
APLT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +1,000,000
- Change %
- Price
- $0.000000
- Shares after
- 1,000,000
- Date
- 19 Dec 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,000,000
- Exercise price
- $1.02
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Consists of compensatory Restricted Stock Units ("RSUs") granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). Each RSU represents a contingent right to receive one share of the issuer's common stock. The RSUs will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date.
Footnote F2
Consists of compensatory Options granted outside of Applied Therapeutics, Inc.'s 2019 Equity Incentive Plan pursuant to the inducement grant exception under Nasdaq Rule 5635(c). The shares subject to the Option will vest in equal annual installments on each of the first two anniversaries of the grant date, subject to the Reporting Person continuing to provide services through each such date.